MMSI vs. HAE, ICUI, INSP, GKOS, AXNX, PRCT, STVN, IRTC, TNDM, and NARI
Should you be buying Merit Medical Systems stock or one of its competitors? The main competitors of Merit Medical Systems include Haemonetics (HAE), ICU Medical (ICUI), Inspire Medical Systems (INSP), Glaukos (GKOS), Axonics (AXNX), PROCEPT BioRobotics (PRCT), Stevanato Group (STVN), iRhythm Technologies (IRTC), Tandem Diabetes Care (TNDM), and Inari Medical (NARI). These companies are all part of the "surgical & medical instruments" industry.
Haemonetics (NYSE:HAE) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
Haemonetics has a net margin of 8.98% compared to Haemonetics' net margin of 7.94%. Merit Medical Systems' return on equity of 22.25% beat Haemonetics' return on equity.
99.7% of Haemonetics shares are held by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are held by institutional investors. 1.8% of Haemonetics shares are held by company insiders. Comparatively, 3.7% of Merit Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Haemonetics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Haemonetics has higher revenue and earnings than Merit Medical Systems. Haemonetics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.
Haemonetics presently has a consensus price target of $108.67, indicating a potential upside of 13.51%. Merit Medical Systems has a consensus price target of $92.78, indicating a potential upside of 13.30%. Given Merit Medical Systems' higher probable upside, equities research analysts plainly believe Haemonetics is more favorable than Merit Medical Systems.
Merit Medical Systems received 29 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 68.90% of users gave Merit Medical Systems an outperform vote while only 60.89% of users gave Haemonetics an outperform vote.
In the previous week, Haemonetics had 10 more articles in the media than Merit Medical Systems. MarketBeat recorded 19 mentions for Haemonetics and 9 mentions for Merit Medical Systems. Haemonetics' average media sentiment score of 1.02 beat Merit Medical Systems' score of 0.56 indicating that Merit Medical Systems is being referred to more favorably in the news media.
Summary
Haemonetics and Merit Medical Systems tied by winning 9 of the 18 factors compared between the two stocks.
Get Merit Medical Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for MMSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MMSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Merit Medical Systems Competitors List
Related Companies and Tools
